ANGN — Stock activity · TradeandTell
ANGN ANGN $10.00 +$0.20 (+2.04%) prev close
Held by
0
portfolios on TandT
Avg position size
—
of holders' portfolios
Financials Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
Income Balance sheet Cash flow
2013 2018 2019 2020 2021 2022 2024 2025 $6.6M $4.0M $1.5M $2.9M $28.3M $2.3M $0 $0 $3.2M $378.0K $640.0K $1.2M $433.0K $0 $0 $0 $3.4M $3.7M $847.0K $1.7M $27.9M $2.3M $0 $0 51.8% 90.6% 57.0% 58.7% 98.5% 100.0% — — $196.0K $12.6M $29.8M $39.0M $48.7M $18.1M $33.7M $24.9M −$397.8K −$14.3M −$38.6M −$55.3M −$39.3M −$30.4M −$45.0M −$37.7M $1.8M −$20.0M −$36.1M −$88.3M −$55.6M −$20.1M $1.2M −$37.7M $632.2K −$20.0M −$42.4M −$79.5M −$53.8M −$55.7M −$51.9M −$39.6M 9.6% -497.0% -2849.0% -2759.7% -189.9% -2420.7% — — 0.04 -1.30 -2.51 -2.76 -1.90 -1.85 -4.25 -2.58
Annual figures · source: Financial Modeling Prep
Peer comparison Symbol Price Today Mkt cap P/E ANGN Angion Biomedica Corp. $1.00 +0.00% $30M — ALNA Allena Pharmaceuticals, Inc. $0.07 +3.16% $0 — AMHV American Hemp Ventures, Inc. $0.98 +0.00% $16M — CHRO Channel Therapeutics Corporation $1.35 +7.14% $9M — CWBR CohBar, Inc. $0.41 +0.00%
Held by traders on TradeandTell No one on the platform currently holds ANGN.
Super investors & insiders Institutions holding (13F)
No tracked institution reports a position in ANGN as of their last filing.
Insider activity (SEC Form 4)
Stock splits Execution date Ratio 2023-06-02 1-for-10reverse
Recent trades on TradeandTell No one on the platform has traded ANGN yet.
Report a bug EMMLF OKYO Pharma Limited $0.01 +0.00% $23M —
MRNS Marinus Pharmaceuticals, Inc. $0.55 +0.00% $30M —
Source: Financial Modeling Prep · peers by sector/industry
Insider activity (SEC Form 4)
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
$ANGN chatter on StockTwits $IFRX Interesting new comment from Guggenheim: wonder if topic comes up Monday w KOL’s and $IFRX
How does INF-904 differ from AMGN's Tavneos (oral C5aR antagonist)? Recall that
Tavneos (i.e., Avacopan) $ANGN showed a late onset of improvement / separation from placebo.
IFRX believes this isn't due to inherent MoA of C5aR inhibition, but rather attributed
to Tavneos's PK pattern (13 weeks to reach steady-state and a steep accumulation
pattern ending around week 8-10), coupled with potential underdosing.
View on StockTwits ↗ Angion Biomedica Corp. Files SEC Form 10-Q $ANGN https://www.marketbeat.com/stocks/NASDAQ/ANGN/sec-filings/
View on StockTwits ↗ Angion Biomedica Corp. Files SEC Form 8-K $ANGN https://www.marketbeat.com/stocks/NASDAQ/ANGN/sec-filings/
View on StockTwits ↗ Angion Biomedica Corp. Files SEC Form S-8 $ANGN https://www.marketbeat.com/stocks/NASDAQ/ANGN/sec-filings/
View on StockTwits ↗ Angion Biomedica Corp. Files SEC Form 10-Q $ANGN https://www.marketbeat.com/stocks/NASDAQ/ANGN/sec-filings/
View on StockTwits ↗ $ANGN - Upcoming quarterly report expected on 21st of August 2023. https://www.macroaxis.com/target-price/ANGN #stocks #earnings
View on StockTwits ↗ $ANGN - Next fiscal quarter end will be on 30th of June 2023. https://www.macroaxis.com/stock-analysis/ANGN/Angion-Biomedica-Corp #stocks #earnings
View on StockTwits ↗ Angion Biomedica Corp. Files SEC Form 3 $ANGN https://www.marketbeat.com/stocks/NASDAQ/ANGN/sec-filings/
View on StockTwits ↗ $ANGN https://www.channelchek.com/news-channel/what-happens-to-your-stock-holding-when-it-is-added-to-a-major-index
View on StockTwits ↗ Angion Biomedica Corp. Files SEC Form 8-K $ANGN https://www.marketbeat.com/stocks/NASDAQ/ANGN/sec-filings/
View on StockTwits ↗ $ANGN
https://ir.elicio.com/news-releases/news-release-details/elicio-therapeutics-announces-positive-interim-data-phase-1/
View on StockTwits ↗ Next reverse splits
$acor
$lixt
$angn became eltx
Haven't looked at sec filings oft offerings yet.
$cjet primed like $sda
View on StockTwits ↗ Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
